Characterization of mutations in aclacinomycin a-non-producing Streptomyces galilaeus strains with altered glycosylation patternsRÄTY, Kaj; HAUTALA, Anne; TORKKELL, Sirke et al.Microbiology (Reading). 2002, Vol 148, pp 3375-3384, issn 1350-0872, 10 p., 11Article

Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitorHAJJI, N; MATEOS, S; PASTOR, N et al.Mutation research. Genetic toxicology and environmental mutagenesis. 2005, Vol 583, Num 1, pp 26-35, issn 1383-5718, 10 p.Article

Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell linesRICHARD, Doriane; MORJANI, Hamid; CHENAIS, Benoit et al.Leukemia research. 2002, Vol 26, Num 10, pp 927-931, issn 0145-2126Article

Long-term follow-up of patients ≥ 60 yr old with acute myeloid leukaemia treated with intensive chemotherapy: A randomised trial of aclarubicin vs. daunorubicin in combination with cytosine arabinoside and thioguanineÖBERG, G; KILLANDER, A; PAUL, C et al.European journal of haematology. 2002, Vol 68, Num 6, pp 376-381, issn 0902-4441Article

The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia : a case studyTSUDA, T; OKAMOTO, Y; SAKAGUCHI, R et al.Journal of international medical research. 2001, Vol 29, Num 1, pp 41-47, issn 0300-0605Article

Leukaemia cell drug resistance and prognostic factors in AMLNØRGAARD, J. M; OLESEN, G; KRISTENSEN, J. S et al.European journal of haematology. 1999, Vol 63, Num 4, pp 219-224, issn 0902-4441Article

Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndromeTAKAGI, S; OHSAKA, A; TAGUCHI, H et al.Internal medicine (Tokyo. 1992). 1998, Vol 37, Num 3, pp 316-319, issn 0918-2918Article

Degree of DNA unwinding caused by the binding of aclacinomycin AUTSUNO, K; TSUBOI, M.Chemical and pharmaceutical bulletin. 1997, Vol 45, Num 10, pp 1551-1557, issn 0009-2363Article

Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclinesLEHNE, G; DE ANGELIS, P; CLAUSEN, O. P. F et al.British journal of cancer. 1996, Vol 74, Num 11, pp 1719-1729, issn 0007-0920Article

Selective delivery of folate-PEG-linked, nanoemulsion-loaded aclacinomycin A to KB nasopharyngeal cells and xenograft : Effect of chain length and amount of folate-PEG linkerOHGUCHI, Yukino; KAWANO, Kumi; HATTORI, Yoshiyuki et al.Journal of drug targeting. 2008, Vol 16, Num 9, pp 30-37, issn 1061-186X, 8 p.Article

Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipidJUNPING WANG; MAITANI, Yoshie; TAKAYAMA, Kozo et al.Journal of pharmaceutical sciences. 2002, Vol 91, Num 4, pp 1128-1134, issn 0022-3549Article

Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemiaNØRGAARD, Jan M; LANGKJER, Sven Tyge; PALSHOF, Torben et al.European journal of haematology. 2001, Vol 66, Num 3, pp 160-167, issn 0902-4441Article

F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103ETIEVANT, C; KRUCZYNSKI, A; BARRET, J.-M et al.Cancer chemotherapy and pharmacology. 2000, Vol 46, Num 2, pp 101-113, issn 0344-5704Article

Inhibition of p34^cdc2 dephosphorylation in DNA damage- and topoisomerase II inactivation-induced G2 arrests in HL-60 cellsSUGIMOTO, K; SASAKI, M; TAMAYOSE, K et al.British journal of haematology. 1999, Vol 105, Num 3, pp 720-729, issn 0007-1048Article

Molecular effects of topoisomerase II inhibitors in AML cell lines : correlation of apoptosis with topoisomerase II activity but not with DNA damage : Apoptosis and Chemotherapy ResistanceGIESELER, F; BAUER, E; NUESSLER, V et al.Leukemia. 1999, Vol 13, Num 11, pp 1859-1863, issn 0887-6924Conference Paper

Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiationTEILLAUD, J. L; GRUEL, N; MONCUIT, J et al.Biomedicine & pharmacotherapy. 1998, Vol 52, Num 6, pp 282-290, issn 0753-3322Article

Enhanced functional capacity of the peritoneal macrophages as antigen presenting cells after aclacinomycin treatment in miceBRAVO-CUELLAR, A; ASTENGO-OSUNA, C; DANERI-NAVARRO, A et al.Biomedicine & pharmacotherapy. 1997, Vol 51, Num 4, pp 181-184, issn 0753-3322Article

Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemiaLIMIN LIU; YANMING ZHANG; DEPEI WU et al.International journal of hematology. 2014, Vol 99, Num 5, pp 603-608, issn 0925-5710, 6 p.Article

Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumoursROGALSKA, Aneta; SZWED, Marzena; JOZWIAK, Zofia et al.Mutation research. Genetic toxicology and environmental mutagenesis (Print). 2010, Vol 700, Num 1-2, pp 1-10, issn 1383-5718, 10 p.Article

Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome : A multicenter study of 112 chinese patientsLI, J. M; SHEN, Y; QIU, Z. C et al.International journal of hematology. 2005, Vol 82, Num 1, pp 48-54, issn 0925-5710, 7 p.Article

Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factorAKASHI, K; ETO, T; SHIBUYA, T et al.Leukemia research. 2000, Vol 24, Num 3, pp 243-248, issn 0145-2126Article

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma : results of ECOG 5282NOVIK, Y; RYAN, L. M; HALLER, D. G et al.Medical oncology (Northwood). 1999, Vol 16, Num 4, pp 261-266, issn 1357-0560Article

Management of malignant pericardial effusion resulting from recurrent cancer with local instillation of aclarubicin hydrochlorideKAWASHIMA, O; KURIHARA, T; KAMIYOSHIHARA, M et al.American journal of clinical oncology. 1999, Vol 22, Num 4, pp 396-398, issn 0277-3732Article

Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia : results of a prospective multicenter phase II trialKERN, W; BRAESS, J; GROTE-METKE, A et al.Leukemia. 1998, Vol 12, Num 10, pp 1522-1526, issn 0887-6924Article

A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancerTOKUHASHI, Y; KIKKAWA, F; NAKASHIMA, N et al.Oncology. 1997, Vol 54, Num 4, pp 281-286, issn 0030-2414Article